1
|
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns. Ann Dermatol Venereol 2024; 151:103243. [PMID: 38325268 DOI: 10.1016/j.annder.2023.103243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/06/2023] [Accepted: 09/05/2023] [Indexed: 02/09/2024]
Affiliation(s)
- M Amini-Adle
- Dermatology Department, Centre Léon Bérard, Lyon, France.
| | - J-P Arnault
- Dermatology Department, Centre Hospitalo-Universitaire, Amiens Picardie, France
| | - F Aubin
- Université de Bourgogne-Franche-Comté, Dermatology Department, Head of the Skin Cancer Unit, Centre Hospitalo-Universitaire de Besançon, Besançon, France; INSERM UMR RIGHT 1098, Besançon, France
| | - N Beneton
- Dermatology Department, Centre Hospitalier, Le Mans, France
| | - G Bens
- Dermatology Department, Centre Hospitalier, Orléans, France
| | - F Brunet-Possenti
- Dermatology Department, Centre Hospitalo-Universitaire Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - P Célerier
- Dermatology Department, Centre Hospitalier La Rochelle-Ré-Aunis, La Rochelle, France
| | - J Charles
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Crumbach
- Dermatology Department, Centre Léon Bérard, Lyon, France
| | - S Dalac
- Dermatology Department, Centre Hospitalo-Universitaire, Dijon, France
| | - S Darras
- Dermatology Department, Centre Hospitalier de Boulogne-sur-Mer, France
| | - J De Quatrebarbes
- Dermatology Department, Centre Hospitalier Annecy Genevois, Annecy, France
| | - M Dinulescu
- Dermatology Department, Centre Hospitalo-Universitaire, Rennes, France
| | - C Dutriaux
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | - C Gaudy
- Dermatology Department, Centre Hospitalo-Universitaire, Marseille, France
| | - E Gérard
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | | | - F Granel-Brocard
- Dermatology Department, Hôpitaux de Brabois Allée de Morvan, Vandoeuvre Les Nancy, France
| | - F Grange
- Dermatology Department, Centre Hospitalier, Valence, France
| | - T Jouary
- Dermatology Department, Hôpital François Mitterrand, Pau, France
| | - N Kramkimel
- Dermatology Department, Centre Hospitalo-Universitaire Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - C Lebbé
- Dermatology Department, Centre Hospitalo-Universitaire Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Y Le Corre
- Dermatology Department, Centre Hospitalo-Universitaire Angers, France
| | - D Legoupil
- Dermatology Department, Centre Hospitalo-Universitaire Régional, Brest, France
| | - C Lesage
- Dermatology Department, Hôpital Saint Eloi, Montpellier, France
| | | | - J-M Lorphelin
- Dermatology Department, Centre Hospitalo-Universitaire, Caen, France
| | - S Mansard
- Dermatology Department, Centre Hospitalo-Universitaire, Clermont Ferrand, France
| | - L Martin
- Dermatology Department, Centre Hospitalo-Universitaire, Angers, France; Groupe Ethique de la Société Française de Dermatologie, France
| | - S Mary-Prey
- Centre Hospitalo-Universitaire Saint André, Bordeaux, France
| | - E Maubec
- Dermatology Department, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - N Meyer
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - C Mignard
- Dermatology Department, Centre Hospitalo-Universitaire, Rouen, France
| | - H Montaudie
- Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France; INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Nice Côte d'Azur, Nice, France
| | - L Mortier
- Dermatology Department, Centre Hospitalier Régional Universitaire, Lille, France
| | - C Nardin
- Université de Bourgogne-Franche-Comté et Centre Hospitalier Universitaire, Besançon, France; IINSERM UMR RIGHT 1098, Besançon, France
| | | | - C Pagès Laurent
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - L Peuvrel
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - Gaelle Quereux
- Dermatology Department, Centre Hospitalo-Universitaire, Nantes Université, Nantes, France; INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
| | - Caroline Robert
- Dermatology Department, Institut Gustave Roussy, Villejuif, France
| | - Philippe Saiag
- Dermatology Department, Centre Hospitalo-Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France
| | - Mélanie Saint-Jean
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - M Samimi
- Dermatology Department, Centre Hospitalo-Universitaire, Tours, France
| | - B Sassolas
- Institute of Oncology & Hematology, Hôpital Morvan, Centre Hospitalier Régional Universitaire, Brest, France
| | - C Scalbert
- Dermatology Department, Centre Hospitalier Ouest Réunion, Saint Paul, Ile de la Réunion, France
| | - F Skowron
- Dermatology Department, Hôpitaux Drome Nord, Romans Sur Isère, France
| | - M Steff
- Dermatology Department, Centre Hospitalier Intercommunal Robert Ballanger, Aulnay sous-Bois, France
| | - P-E Stoebner
- Dermatology Department, Centre Hospitalo-Universitaire, Nîmes, France
| | - S Trablesi
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Visseaux
- Polyclinique Reims Bezannes, Bezannes, France
| | - O Zehou
- Dermatology Department, Centre Hospitalo-Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - A Boespflug
- Dermatology Department, Centre Hospitalier Henri Mondor, Villejuif, France
| |
Collapse
|
2
|
Nardin C, Mammano F. Measurement of Ca 2+ Uptake Through Connexin Hemichannels. Methods Mol Biol 2024; 2801:97-109. [PMID: 38578416 DOI: 10.1007/978-1-0716-3842-2_8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2024]
Abstract
Increasing evidence points to deregulated flux of ionized calcium (Ca2+) mediated by hyperactive mutant connexin (Cx) hemichannels (HCs) as a common gain-of-function etiopathogenetic mechanism for several diseases, ranging from skin disorders to nervous system defects. Furthermore, the opening of nonmutated Cx HCs is associated with an impressive list of widespread diseases including, but not limited to, ischemia/stroke, Alzheimer's disease, and epilepsy. HC inhibitors are attracting a growing attention due to their therapeutic potential for numerous pathologies. This chapter describes a quantitative method to measure Ca2+ uptake though HCs expressed in cultured cells. The assay we developed can be used to probe HC activity as wells as to test HC inhibitors. Furthermore, with minor changes it can be easily adapted to high-throughput high-content platforms and/or primary cells and microtissues.
Collapse
Affiliation(s)
- Chiara Nardin
- Institute of Biochemistry and Cell Biology, Italian National Research Council, Rome, Italy
- , Genoa, Italy
| | - Fabio Mammano
- Institute of Biochemistry and Cell Biology, Italian National Research Council, Rome, Italy.
- Department of Physics and Astronomy "G. Galilei", University of Padova, Padova, Italy.
| |
Collapse
|
3
|
Bressan A, Faggin E, Donato M, Tonon L, Buso R, Nardin C, Tiepolo M, Cinetto F, Scarpa R, Agostini C, Pauletto P, Ventura L, Fusaro M, Felice C, Rattazzi M. NETosis in Acute Thrombotic Disorders. Semin Thromb Hemost 2023; 49:709-715. [PMID: 37308098 DOI: 10.1055/s-0043-1769510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
The release of extracellular traps by neutrophils (NETs) represents a novel active mechanism of cell death that has been recently implicated in the pathogenesis of thrombotic disorders. The aim of this study was to investigate the generation of NETs in different groups of patients with acute thrombotic events (ATEs) and to establish whether NETs markers can predict the risk of new cardiovascular events. We performed a case-control study of patients with ATE, including acute coronary syndrome (n = 60), cerebrovascular accident (n = 50), and venous thromboembolism (n = 55). Control subjects (n = 70) were identified among patients admitted for acute chest pain and in which a diagnosis of ATE was excluded. Serum levels of NET markers and neutrophil activation, such as myeloperoxidase (MPO)-DNA complexes, neutrophil gelatinase-associated lipocalin, polymorphonuclear neutrophil elastase, lactoferrin, and MPO, were measured in each patient. We found that circulating levels of MPO-DNA complexes were significantly increased in patients with ATE (p < 0.001) compared with controls and that this association remained significant even after fully adjustment for traditional risk factors (p = 0.001). A receiver operating characteristics analysis of circulating MPO-DNA complexes in discriminating between controls and patients with ATE showed a significant area under the curve of 0.76 (95% confidence interval: 0.69-0.82). After a median follow-up of 40.7 (± 13.8) months, 24 out of the 165 patients with ATE presented a new cardiovascular event and 18 patients died. None of the markers under investigation influenced survival or the incidence of new cardiovascular events. In conclusion, we found that increase of markers of NETosis can be observed in acute thrombotic conditions, occurring both on the arterial and venous site. Nevertheless, the level of neutrophil markers measured during the ATE is not predictive of future risk of mortality and cardiovascular events.
Collapse
Affiliation(s)
| | | | - Maristella Donato
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Luca Tonon
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Roberta Buso
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Chiara Nardin
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Marta Tiepolo
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Francesco Cinetto
- Department of Medicine, University of Padova, Padova, Italy
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Riccardo Scarpa
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Carlo Agostini
- Department of Medicine, University of Padova, Padova, Italy
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Paolo Pauletto
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Laura Ventura
- Department of Statistical Sciences, University of Padova, Padova, Italy
| | | | - Carla Felice
- Department of Medicine, University of Padova, Padova, Italy
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| | - Marcello Rattazzi
- Department of Medicine, University of Padova, Padova, Italy
- Medicine 1^, Ca' Foncello University Hospital, Treviso, Italy
| |
Collapse
|
4
|
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37:1777-1784. [PMID: 37113040 DOI: 10.1111/jdv.19134] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 03/29/2023] [Indexed: 04/29/2023]
Abstract
BACKGROUND Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS) or Mycosis Fungoides (MF). OBJECTIVES The real-world French OMEGA study aimed to describe effectiveness and tolerability of mogamulizumab in adult patients with CTCL, overall and according to the disease (SS or MF). METHODS In this retrospective study, patients treated with mogamulizumab for SS or MF were included from 14 French expert centres. The overall response rate (ORR) under treatment was described (primary criterion), as well as treatment use and safety data. RESULTS The 122 analysed patients (69 SS, 53 MF) were aged 66.6 ± 12.1 years at mogamulizumab initiation, and their median disease duration was 2.5 years (IQR: 1.3-5.6). Prior to treatment start, they received a median of three systemic CTCL therapies (2-5). Overall, 77.8% of patients suffered from advanced disease (Stage IIB-IVB), with frequent blood (B1/B2) involvement (67.5%). Over the treatment period (median: 4.6 months, 2.1-7.2), 96.7% of patients received all the planned mogamulizumab infusions. Among the 109 patients evaluable for effectiveness, ORR was 58.7% (95% CI [48.9-68.1]) overall, 69.5% [56.1-80.8] in SS and 46.0% [31.8-60.7] in MF. Compartmental response in the blood was observed in 81.8% [69.1-90.9] of SS patients. Skin responses were observed in 57.0% [47.0-66.5] of patients overall, 66.7% [52.9-78.6] in SS and 46.0% [31.8-60.7] in MF. The most common serious adverse drug reactions were rash (8.1% of patients) and infusion-related reactions (2.4%) which led to treatment discontinuation in 7.3% and 0.8% of patients, respectively. One patient with SS died from mogamulizumab-related tumour lysis syndrome. CONCLUSIONS This large French study confirmed the effectiveness and tolerability of mogamulizumab in SS and MF patients in routine medical practice.
Collapse
Affiliation(s)
- M Beylot-Barry
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - G Quereux
- Dermatology Department, Nantes University Hospital, University of Nantes, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, Nantes, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, CHU Besancon, Besancon, France
- INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - A-B Duval-Modeste
- Department of Dermatology, INSERM U519, Rouen University Hospital, Rouen, France
| | - O Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - S Dalac-Rat
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
- Department of Dermatology, HTCC, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - A Pham-Ledard
- BoRdeaux Institute of Oncology, INSERM U1312, Team 5, Bordeaux University, Bordeaux, France
- Dermatology Department, CHU Bordeaux, Bordeaux, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M D'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - F Grange
- Department of Dermatology, Valence Hospital, Valence, France
| | - V Braniste
- Kyowa Kirin Pharma, Medical Affairs, Neuilly-sur-Seine, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
5
|
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L. Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas. Cancer Immunol Immunother 2023:10.1007/s00262-023-03449-9. [PMID: 37067554 DOI: 10.1007/s00262-023-03449-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Accepted: 04/06/2023] [Indexed: 04/18/2023]
Abstract
Trichoblastic carcinoma is a rare malignant cutaneous adnexal tumor with a risk of local invasion and distant metastasis. As of today, there is no consensus for the treatment of locally advanced or metastatic trichoblastic carcinoma. "AcSé Nivolumab" is a multi-center Phase II basket clinical trial (NCT03012581) evaluating the safety and efficacy of nivolumab in several cohorts of rare, advanced cancers. Here we report the results of nivolumab in patients with trichoblastic carcinoma. Of the eleven patients enrolled in the study, five patients had been previously treated by sonic hedgehog inhibitors. The primary endpoint 12-week objective response rate was 9.1% (N = 1/11) with 1 partial response. Six patients who progressed under previous lines of treatment showed stable disease at 12 weeks, reflecting a good control of the disease with nivolumab. Furthermore, 54.5% of the patients (N = 6/11) had their disease under control at 6 months. The 1-year overall survival was 80%, and the median progression-free survival was 8.4 months (95%CI, 5.7 to NA). With 2 responders (2 complete responses), the best response rate to nivolumab at any time was 18.2% (95%CI, 2.3-51.8%). No new safety signals were identified, and adverse events observed herein were previously described and well known with nivolumab monotherapy. These results are promising, suggesting that nivolumab might be an option for patients with advanced trichoblastic carcinomas. Further studies on larger cohorts are necessary to confirm these results and define the role of nivolumab in the treatment of trichoblastic carcinomas.
Collapse
Affiliation(s)
- E Toulemonde
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France.
| | - S Chevret
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M Battistella
- Department of Pathology, Saint Louis Hospital, AP-HP, Université Paris Cité, INSERM U976, Paris, France
- CARADERM Network, Lille, France
| | - E M Neidhardt
- Department of Oncology, Centre Léon Berard, Lyon, France
| | - C Nardin
- Department of Dermatology, CHU Besançon and INSERM 1098, Besançon, France
| | - F Le Du
- Department of Oncology, CLCC Eugène Marquis, Rennes, France
| | - N Meyer
- Department of Oncodermatology, IUC and CHU Toulouse, Toulouse, France
| | - M Véron
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - L Gambotti
- Department of Clinical Research, Institut National Contre Le Cancer (INCa), Paris, France
| | | | - P Jamme
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - C Chaffaut
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M De Pontville
- Department of Dermatology, CHU Caen, Caen, France
- CARADERM Network, Lille, France
| | - E Saada-Bouzid
- Department of Medical Oncology, Centre Antoine Lacassagne, Côte d'Azur University, Nice, France
| | - M Beylot-Barry
- Department of Dermatology, CHU Bordeaux, INSERM U1312, Bordeaux, France
- CARADERM Network, Lille, France
| | - C Simon
- Département R&D Unicancer, Paris, France
| | - T Jouary
- Department of Dermatology, François Mitterrand Hospital, Pau, France
- CARADERM Network, Lille, France
| | - A Marabelle
- Department of Therapeutic Innovations and Early Clinical Trials, INSERM U1015 & CIC1428, University of Paris Saclay, Gustave Roussy, Villejuif, France
| | - L Mortier
- Department of Dermatology, Claude Huriez Hospital, CARADERM and University of Lille, U1189 Inserm, 59000, Lille, France
- CARADERM Network, Lille, France
| |
Collapse
|
6
|
Peres C, Sellitto C, Nardin C, Putti S, Orsini T, Di Pietro C, Marazziti D, Vitiello A, Calistri A, Rigamonti M, Scavizzi F, Raspa M, Zonta F, Yang G, White TW, Mammano F. Antibody gene transfer treatment drastically improves epidermal pathology in a keratitis ichthyosis deafness syndrome model using male mice. EBioMedicine 2023; 89:104453. [PMID: 36736132 PMCID: PMC9926223 DOI: 10.1016/j.ebiom.2023.104453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 12/30/2022] [Accepted: 01/11/2023] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Keratitis ichthyosis deafness (KID) syndrome is a rare disorder caused by hemichannel (HC) activating gain-of-function mutations in the GJB2 gene encoding connexin (Cx) 26, for which there is no cure, or current treatments based upon the mechanism of disease causation. METHODS We applied Adeno Associated Virus (AAV) mediated mAb gene transfer (AAVmAb) to treat the epidermal features of KID syndrome with a well-characterized HC blocking antibody using male mice of a murine model that replicates the skin pathology of the human disease. FINDINGS We demonstrate that in vivo AAVmAb treatment significantly reduced the size and thickness of KID lesions, in addition to blocking activity of mutant HCs in the epidermis in vivo. We also show that AAVmAb treatment eliminated abnormal keratinocyte proliferation and enlarged cell size, decreased apoptosis, and restored the normal distribution of keratin expression. INTERPRETATION Our findings reinforce the critical role played by increased HC activity in the skin pathology associated with KID syndrome. They also underscore the clinical potential of anti-HC mAbs coupled with genetic based delivery systems for treating the underlying mechanistic basis of this disorder. Inhibition of HC activity is an ideal therapeutic target in KID syndrome, and the genetic delivery of mAbs targeted against mutant HCs could form the basis of new therapeutic interventions to treat this incurable disease. FUNDING Fondazione Telethon grant GGP19148 and University of Padova grant Prot. BIRD187130 to FM; Foundation for Ichthyosis and Related Skin Types (FIRST) and National Institutes of Health grant EY 026911 to TWW.
Collapse
Affiliation(s)
- Chiara Peres
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Caterina Sellitto
- Department of Physiology and Biophysics, Stony Brook University, T5-147, Basic Science Tower; Stony Brook, NY, 11794-8661, USA
| | - Chiara Nardin
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Sabrina Putti
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Tiziana Orsini
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Chiara Di Pietro
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Daniela Marazziti
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Adriana Vitiello
- Department of Molecular Medicine, University of Padova, 35121, Padova, Italy
| | - Arianna Calistri
- Department of Molecular Medicine, University of Padova, 35121, Padova, Italy
| | | | - Ferdinando Scavizzi
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Marcello Raspa
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy
| | - Francesco Zonta
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China
| | - Guang Yang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China
| | - Thomas W White
- Department of Physiology and Biophysics, Stony Brook University, T5-147, Basic Science Tower; Stony Brook, NY, 11794-8661, USA.
| | - Fabio Mammano
- Institute of Biochemistry and Cell Biology, Italian National Research Council, 00015 Monterotondo, Rome, Italy; Department of Physics and Astronomy "G. Galilei", University of Padova, 35131, Padova, Italy.
| |
Collapse
|
7
|
Marguier A, Perreira V, Wespiser M, Lecoester B, Boullerot L, Malfroy M, Nardin C, Laheurte C, Orillard E, Adotevi O. 210P Anti-CTLA-4 overcomes inhibitory effect of PD1high regulatory T cell on circulating antitumor CD4+ Th1 response in patients treated by anti-PD(L)-1. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
8
|
Peres C, Nardin C, Yang G, Mammano F. Commercially derived versatile optical architecture for two-photon STED, wavelength mixing and label-free microscopy. Biomed Opt Express 2022; 13:1410-1429. [PMID: 35414982 PMCID: PMC8973165 DOI: 10.1364/boe.444525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 01/03/2022] [Accepted: 01/06/2022] [Indexed: 06/14/2023]
Abstract
Multimodal microscopy combines multiple non-linear techniques that take advantage of different optical processes to generate contrast and increase the amount of information that can be obtained from biological samples. However, the most advanced optical architectures are typically custom-made and often require on-site adjustment of optical components performed by trained personnel for optimal performance. Here, we describe a hybrid system we built based on a commercial upright microscope. We show that our multimodal imaging platform can be used to seamlessly perform two-photon STED, wavelength mixing and label-free microscopy in both ex vivo and in vivo turbid samples. The system is stable and endowed with remote alignment hardware that ensures long-term operability also for non-expert users, using the alignment protocol described in this article and in the related material. This optical architecture is an important step forward towards a wider practical applicability of non-linear optics to bioimaging.
Collapse
Affiliation(s)
- Chiara Peres
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Rome, Italy
- Department of Physics and Astronomy “G. Galilei”, University of Padova, 35131 Padova, Italy
| | - Chiara Nardin
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Rome, Italy
| | - Guang Yang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 201210 Shanghai, China
| | - Fabio Mammano
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Rome, Italy
- Department of Physics and Astronomy “G. Galilei”, University of Padova, 35131 Padova, Italy
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, 201210 Shanghai, China
| |
Collapse
|
9
|
Donati V, Peres C, Nardin C, Scavizzi F, Raspa M, Ciubotaru CD, Bortolozzi M, Pedersen MG, Mammano F. Calcium Signaling in the Photodamaged Skin: In Vivo Experiments and Mathematical Modeling. Function (Oxf) 2021; 3:zqab064. [PMID: 35330924 PMCID: PMC8788836 DOI: 10.1093/function/zqab064] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2021] [Revised: 11/23/2021] [Accepted: 11/23/2021] [Indexed: 01/07/2023] Open
Abstract
The epidermis forms an essential barrier against a variety of insults. The overall goal of this study was to shed light not only on the effects of accidental epidermal injury, but also on the mechanisms that support laser skin resurfacing with intra-epidermal focal laser-induced photodamage, a widespread medical practice used to treat a range of skin conditions. To this end, we selectively photodamaged a single keratinocyte with intense, focused and pulsed laser radiation, triggering Ca2+ waves in the epidermis of live anesthetized mice with ubiquitous expression of a genetically encoded Ca2+ indicator. Waves expanded radially and rapidly, reaching up to eight orders of bystander cells that remained activated for tens of minutes, without displaying oscillations of the cytosolic free Ca2+ concentration ([Formula: see text]). By combining in vivo pharmacological dissection with mathematical modeling, we demonstrate that Ca2+ wave propagation depended primarily on the release of ATP, a prime damage-associated molecular patterns (DAMPs), from the hit cell. Increments of the [Formula: see text] in bystander cells were chiefly due to Ca2+ release from the endoplasmic reticulum (ER), downstream of ATP binding to P2Y purinoceptors. ATP-dependent ATP release though connexin hemichannels (HCs) affected wave propagation at larger distances, where the extracellular ATP concentration was reduced by the combined effect of passive diffusion and hydrolysis due to the action of ectonucleotidases, whereas pannexin channels had no role. Bifurcation analysis suggests basal keratinocytes have too few P2Y receptors (P2YRs) and/or phospholipase C (PLC) to transduce elevated extracellular ATP levels into inositol trisphosphate (IP3) production rates sufficiently large to sustain [Formula: see text] oscillations.
Collapse
Affiliation(s)
- Viola Donati
- Department of Physics and Astronomy “G. Galilei”, University of Padova, 35131 Padova, Italy
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Monterotondo (RM), Italy
| | - Chiara Peres
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Monterotondo (RM), Italy
| | - Chiara Nardin
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Monterotondo (RM), Italy
| | - Ferdinando Scavizzi
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Monterotondo (RM), Italy
| | - Marcello Raspa
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Monterotondo (RM), Italy
| | | | - Mario Bortolozzi
- Department of Physics and Astronomy “G. Galilei”, University of Padova, 35131 Padova, Italy
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Monterotondo (RM), Italy
- Foundation for Advanced Biomedical Research, Veneto Institute of Molecular Medicine (VIMM), 35129 Padova (PD), Italy
| | - Morten Gram Pedersen
- Department of Information Engineering, University of Padova, 35131 Padova (PD), Italy
- Department of Mathematics “Tullio Levi-Civita”, University of Padova, 35121 Padova (PD), Italy
| | - Fabio Mammano
- Department of Physics and Astronomy “G. Galilei”, University of Padova, 35131 Padova, Italy
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Monterotondo (RM), Italy
| |
Collapse
|
10
|
Nardin C, Peres C, Putti S, Orsini T, Colussi C, Mazzarda F, Raspa M, Scavizzi F, Salvatore AM, Chiani F, Tettey-Matey A, Kuang Y, Yang G, Retamal MA, Mammano F. Connexin Hemichannel Activation by S-Nitrosoglutathione Synergizes Strongly with Photodynamic Therapy Potentiating Anti-Tumor Bystander Killing. Cancers (Basel) 2021; 13:cancers13205062. [PMID: 34680212 PMCID: PMC8533914 DOI: 10.3390/cancers13205062] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Revised: 10/02/2021] [Accepted: 10/06/2021] [Indexed: 12/22/2022] Open
Abstract
Simple Summary Bystander effects depend on direct cell-cell communication and/or paracrine signaling mediated by the release of soluble factors into the extracellular environment and may greatly influence therapy outcome. Although the limited data available suggest a role for intercellular gap junction channels, far less is known about the role of connexin hemichannels. Here, we investigated bystander effects induced by photodynamic therapy in syngeneic murine melanoma models in vivo. We determined that (i) photoactivation of a photosensitizer triggered calcium-dependent cell death pathways in both irradiated and bystander tumor cells; (ii) hemichannel activity and adenosine triphosphate release were key factors for the induction of bystander cell death; and (iii) bystander cell killing and antitumor response elicited by photodynamic therapy were greatly enhanced by combination treatment with S-nitrosoglutathione, which promoted hemichannel opening in these experimental conditions. Therefore, these findings in a preclinical model have important translational potential. Abstract In this study, we used B16-F10 cells grown in the dorsal skinfold chamber (DSC) preparation that allowed us to gain optical access to the processes triggered by photodynamic therapy (PDT). Partial irradiation of a photosensitized melanoma triggered cell death in non-irradiated tumor cells. Multiphoton intravital microscopy with genetically encoded fluorescence indicators revealed that bystander cell death was mediated by paracrine signaling due to adenosine triphosphate (ATP) release from connexin (Cx) hemichannels (HCs). Intercellular calcium (Ca2+) waves propagated from irradiated to bystander cells promoting intracellular Ca2+ transfer from the endoplasmic reticulum (ER) to mitochondria and rapid activation of apoptotic pathways. Combination treatment with S-nitrosoglutathione (GSNO), an endogenous nitric oxide (NO) donor that biases HCs towards the open state, greatly potentiated anti-tumor bystander killing via enhanced Ca2+ signaling, leading to a significant reduction of post-irradiation tumor mass. Our results demonstrate that HCs can be exploited to dramatically increase cytotoxic bystander effects and reveal a previously unappreciated role for HCs in tumor eradication promoted by PDT.
Collapse
Affiliation(s)
- Chiara Nardin
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Chiara Peres
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Sabrina Putti
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Tiziana Orsini
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Claudia Colussi
- Institute for Systems Analysis and Computer Science “A. Ruberti” (IASI)-CNR, 00168 Rome, Italy;
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy
| | - Flavia Mazzarda
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
- Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23508, USA
| | - Marcello Raspa
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Ferdinando Scavizzi
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Anna Maria Salvatore
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Francesco Chiani
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Abraham Tettey-Matey
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
| | - Yuanyuan Kuang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; (Y.K.); (G.Y.)
| | - Guang Yang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; (Y.K.); (G.Y.)
| | - Mauricio A. Retamal
- Universidad del Desarrollo, Centro de Fisiología Celular e Integrativa, Facultad de Medicina Clínica Alemana, Santiago 7780272, Chile;
| | - Fabio Mammano
- Institute of Biochemistry and Cell Biology (IBBC)-CNR, 00015 Rome, Italy; (C.N.); (C.P.); (S.P.); (T.O.); (F.M.); (M.R.); (F.S.); (A.M.S.); (F.C.); (A.T.-M.)
- Department of Physics and Astronomy “G. Galilei”, University of Padova, 35131 Padova, Italy
- Correspondence:
| |
Collapse
|
11
|
Paolacci F, Quinci G, Nardin C, Vezzari V, Marino A, Ciucci M. Bolted flange joints equipped with FBG sensors in industrial piping systems subjected to seismic loads. J Loss Prev Process Ind 2021. [DOI: 10.1016/j.jlp.2021.104576] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Guillaume T, Puzenat E, Popescu D, Aubin F, Nardin C. Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department. Br J Dermatol 2021; 185:1056-1058. [PMID: 34107076 DOI: 10.1111/bjd.20569] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 06/07/2021] [Accepted: 06/07/2021] [Indexed: 11/29/2022]
Affiliation(s)
- T Guillaume
- University Hospital, Dermatology Department and Institut Régional Fédératif de Cancérologie, Besançon, France
| | - E Puzenat
- University Hospital, Dermatology Department and Institut Régional Fédératif de Cancérologie, Besançon, France
| | - D Popescu
- University Hospital, Dermatology Department and Institut Régional Fédératif de Cancérologie, Besançon, France
| | - F Aubin
- University Hospital, Dermatology Department and Institut Régional Fédératif de Cancérologie, Besançon, France.,University of Franche-Comté, Inserm 1098 RIGHT, Besançon, France
| | - C Nardin
- University Hospital, Dermatology Department and Institut Régional Fédératif de Cancérologie, Besançon, France.,University of Franche-Comté, Inserm 1098 RIGHT, Besançon, France
| |
Collapse
|
13
|
Puato M, Zambon A, Nardin C, Faggin E, Pesavento R, Spinazzè A, Pauletto P, Rattazzi M. Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. Cardiovasc Ther 2021; 2021:5546800. [PMID: 33976708 PMCID: PMC8087481 DOI: 10.1155/2021/5546800] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Revised: 04/06/2021] [Accepted: 04/08/2021] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND AND AIMS A relevant role is emerging for functional foods in cardiovascular prevention. The aim of this study was to assess the effect of a nutraceutical multitargeted approach on lipid profile and inflammatory markers along with vascular remodelling in a cohort of dyslipidemic subjects without history of cardiovascular (CV) disease. METHODS AND RESULTS We enrolled 25 subjects (mean age 48.2 years) with low to moderate CV risk profile and total cholesterol (TC) levels between 150 and 250 mg/dl. The patients were assigned to receive for one year a tablet/die of a nutraceutical combination containing red yeast rice (RYR) extract (Monacolin 3 mg/tablet) and coenzyme Q10 (30 mg/tablet). Treatment with the nutraceutical compounds led to a significant reduction of TC (from 227 to 201 mg/dl, p < 0.001), LDL-c (from 150 to 130 mg/dl, p = 0.001), triglycerides (from 121 to 109 mg/dl, p = 0.013), non-HDL-cholesterol (from 168 to 141 mg/dl, p < 0.001), hs-CRP (from 1.74 to 1.20 mg/l, p = 0.015), and osteoprotegerin (from 1488 to 1328 pg/ml, p = 0.045). Levels of HDL-c, Lp(a), glucose, liver enzyme, CPK, or creatinine did not change over time. An ultrasound study was performed to assess changes in mean carotid intima-media thickness (IMT) and maximum IMT (M-MAX) as well as modification in local carotid stiffness by means of determining the carotid compliance coefficient (CC) and distensibility coefficient (DC). At the end of the treatment, we observed small but significant reductions in both mean-IMT (from 0.62 to 0.57 mm, p = 0.022) and M-MAX (from 0.79 to 0.73 mm, p = 0.002), and an improvement in carotid elasticity (DC from 22.4 to 24.3 × 10-3/kPa, p = 0.006 and CC from 0.77 to 0.85 mm2/kPa, p = 0.019). CONCLUSIONS A long-term treatment with a combination of RYR and coenzyme Q10 showed lipid-lowering activity along with a reduction of inflammatory mediators and an improvement of vascular properties in young subjects with a low-to-moderate CV risk profile.
Collapse
Affiliation(s)
| | - Alberto Zambon
- Department of Medicine (DIMED), University of Padova, Italy
| | - Chiara Nardin
- Department of Medicine (DIMED), University of Padova, Italy
- Medicina Generale I^, Ca' Foncello Hospital, Treviso, Italy
| | | | | | - Alice Spinazzè
- Department of Medicine (DIMED), University of Padova, Italy
| | - Paolo Pauletto
- ORAS Rehabilitation Hospital, Motta di Livenza, Treviso, Italy
| | - Marcello Rattazzi
- Department of Medicine (DIMED), University of Padova, Italy
- Medicina Generale I^, Ca' Foncello Hospital, Treviso, Italy
| |
Collapse
|
14
|
De Lucchi L, Nardin C, Sponchiado A, Raggi D, Faggin E, Martini E, Pagliara V, Callegari E, Caberlotto L, Plebani M, Pauletto P, Cinetto F, Agostini C, Villalta S, Rattazzi M. Serum uric acid levels and the risk of recurrent venous thromboembolism. J Thromb Haemost 2021; 19:194-201. [PMID: 33078502 DOI: 10.1111/jth.15139] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 10/06/2020] [Accepted: 10/09/2020] [Indexed: 08/31/2023]
Abstract
Essentials Increase in serum uric acid (SUA) levels has been widely associated with higher risk of cardiovascular disease. We investigated the link between SUA levels and the risk of venous thromboembolism (VTE) recurrence. Patients with SUA levels ≥ 4.38 mg/dL showed a three-fold increase in the risk of VTE recurrence. Elevated SUA levels are associated with increased risk of recurrent VTE independently from traditional risk factors. ABSTRACT: Background The link between serum uric acid (SUA) and the risk of cardiovascular disease is well established. However, the impact of SUA levels on the risk of venous thromboembolism (VTE) recurrence is unknown. Objectives To investigate the association between SUA and the risk of VTE recurrence. Patients and Methods We performed a monocenter, prospective study on 280 patients with a previous episode of VTE that completed the oral anticoagulant period. SUA levels at enrollment were correlated with the risk of VTE recurrence (mean follow-up 71.1 ± 29.2 months). Results Patients were stratified according to SUA tertiles distribution at baseline (tertiles cut-off: I ≤ 4.37 mg/dL, II 4.38--5.54 mg/dL, III ≥ 5.55 mg/dL). Fifty episodes of VTE recurrence occurred during the follow-up and Kaplan-Meier survival analysis showed that subjects in the lower tertile of SUA distribution had significantly lower risk of future VTE recurrence (P = .003). No differences were seen among patients belonging to the second and the third tertile of SUA distribution. A multivariate Cox regression analysis showed that higher tertiles of SUA distribution had about three-fold increase in the risk of VTE recurrence as compared to subjects with SUA ≤ 4.37, independently from potential confounders (hazard ratio [HR] 3.04, 95% confidence interval [CI] 1.15--8.05 P = .025). Moreover, we observed that the adjusted hazard of VTE recurrence increased by 30% for each additional unit of SUA (mg/dL; HR 1.30, 95% CI 1.01--1.22, P = .040). Conclusion Elevated SUA levels are associated with increased risk of future VTE recurrence independently from traditional risk factors.
Collapse
Affiliation(s)
- Lara De Lucchi
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
| | - Chiara Nardin
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
| | | | - Davide Raggi
- Department of Economics, University of Bologna, Bologna, Italy
| | | | - Elena Martini
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
| | - Valeria Pagliara
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
| | - Elena Callegari
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
| | - Livio Caberlotto
- Laboratory Medicine, Ca' Foncello University Hospital, Treviso, Italy
| | - Mario Plebani
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| | - Paolo Pauletto
- ORAS Rehabilitation Hospital, Motta di Livenza, Treviso, Italy
| | - Francesco Cinetto
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| | - Carlo Agostini
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| | - Sabina Villalta
- Medicina Generale, Castelfranco Veneto Hospital, Castelfranco Veneto, Italy
| | - Marcello Rattazzi
- Medicina Generale I^, Ca' Foncello University Hospital, Treviso, Italy
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| |
Collapse
|
15
|
Ortolan A, Ramonda R, Lorenzin M, Pesavento R, Spinazzè A, Felicetti M, Nardin C, Rattazzi M, Doria A, Puato M. Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. Clin Exp Rheumatol 2021; 39:158-161. [PMID: 32452348 DOI: 10.55563/clinexprheumatol/3qiqk3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Accepted: 04/07/2020] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Our aim was to evaluate subclinical atherosclerosis progression during 5 years of anti-tumour necrosis factor (TNF)-α treatment in psoriatic arthritis (PsA) patients. METHODS Thirty-two consecutive PsA patients starting TNF-α inhibitors were enrolled and evaluated at baseline (T0), 2 years (FU1) and 5 years (FU2) of treatment. Arterial structural properties were evaluated by B-mode ultrasound of mean carotid intima-media thickness (mean-IMT) and maximum IMT (M-MAX) in each segment (common, bulb, internal), bilaterally. Endothelial function was assessed by post-occlusion flow-mediated dilation (FMD) of the brachial artery using high-sensitivity ultrasonography. Treatment response was studied through DAS28 (disease activity score) and inflammatory biomarkers (C-reactive protein, TNF-α, osteoprotegerin). Metrologic and metabolic data were collected. RESULTS At T1, a significant decrease of DAS28 (4.2±0.7 vs. 2.3±0.8, p<0.001) and CRP (11.25±9.16 vs. 2.91±1.72, p<0.01) was observed. Efficacy was preserved at FU2 (DAS28 2.4±0.9, CRP 2.73±2.51; p=ns vs. FU1). Systolic blood pressure and BMI remained stable throughout the follow-up, while diastolic blood pressure decreased significantly from FU1 to FU2 (80±10 vs. 74±7 mmHg, p=0.001). From T0 to FU1 there was an increase of IMT-mean and M-MAX (0.7±0.1 vs. 0.9±0.4 and 0.9±0.2 vs. 1.1±0.4, p<0.01). At FU2, IMT-mean and M-max did not change significantly (0.9±0.3 and 1.1±0.3, p=ns vs. FU1). No significant variation in FMD values was observed during the study period. CONCLUSIONS A slight progression of subclinical atherosclerosis in PsA was observed in the first 2 years of anti-TNF-α treatment. This process seemed to decelerate in follow-up extension to 5 years.
Collapse
Affiliation(s)
- Augusta Ortolan
- Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy
| | - Roberta Ramonda
- Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy.
| | | | - Raffaele Pesavento
- Clinica Medica 3, Department of Medicine DIMED, University of Padova, Italy
| | - Alice Spinazzè
- Clinica Medica 3, Department of Medicine DIMED, University of Padova, Italy
| | - Mara Felicetti
- Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy
| | - Chiara Nardin
- Medicina Interna I, Ospedale Ca Foncello, Treviso, Italy
| | | | - Andrea Doria
- Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy
| | - Massimo Puato
- Clinica Medica 3, Department of Medicine DIMED, University of Padova; and Dipartimento di Medicina, Ospedaledi Mirano, Venezia, Italy
| |
Collapse
|
16
|
Fréchet L, Gerazime A, Popescu D, Woronoff A, Dupond A, Puzenat E, Nardin C, Aubin F. Étude épidémiologique et descriptive des lymphomes cutanés à partir des données du registre des tumeurs du Doubs de 1979 à 2016. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Oro S, Battistella M, d’Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereur O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M. Changements dans l’épidémiologie des lymphomes cutanés primitifs en France : une analyse de 8593 patients du registre du Groupe Français d’Etude des Lymphomes Cutanés (GFELC). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudie H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C. Effets indésirables tardifs des anti-PD1 : étude nationale française multicentrique prospective (MELBASE). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Guillaume T, Puzenat E, Popescu D, Lamotte M, Zanella A, Chevalier G, Aubin F, Nardin C. Efficacité du cémiplimab en vie réelle dans le traitement du carcinome épidermoïde cutané avancé. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Gallais-Serezal I, Puzenat E, Moreau J, Dresco F, Nardin C, Aubin F. Impact de la COVID-19 chez les patients psoriasiques traités par biothérapies en zone d’exposition à haut risque (Franche-Comté). Ann Dermatol Venereol 2020. [PMCID: PMC7688268 DOI: 10.1016/j.annder.2020.09.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Introduction Matériel et méthodes Résultats Discussion
Collapse
|
21
|
Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Ingen-Housz-Oro S, Battistella M, d'Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereure O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M. Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br J Dermatol 2020; 184:1059-1067. [PMID: 33131055 DOI: 10.1111/bjd.19644] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time. OBJECTIVES The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients. METHODS Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included. RESULTS The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time. CONCLUSIONS Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.
Collapse
Affiliation(s)
- G Dobos
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - A de Masson
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - C Ram-Wolff
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - M Beylot-Barry
- Dermatology Department, Université de Bordeaux, Bordeaux, France
| | - A Pham-Ledard
- Dermatology Department, Université de Bordeaux, Bordeaux, France
| | - N Ortonne
- Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - S Ingen-Housz-Oro
- Dermatology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - M Battistella
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France.,Pathology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - M d'Incan
- Dermatology and Cutaneous Oncology, Estaing University Hospital, Université de Clermont-Ferrand, Clermont-Ferrand, France
| | - J Rouanet
- Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France
| | - F Franck
- Pathology Department, NHE Clermont et SIPATH UNILABS, Clermont-Ferrand, France
| | | | - N Franck
- Dermatology Department, Cochin Hospital, AP-HP, Paris, France
| | - A Carlotti
- Pathology Department, Cochin Hospital, AP-HP, Paris, France
| | - S Boulinguez
- Dermatology Department, Cahors Hospital, Toulouse, France
| | - L Lamant
- Pathology and Cytopathology Department, Institut Universitaire du Cancer Toulouse, Toulouse, France
| | - T Petrella
- Pathology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - S Dalac
- Dermatology Department, Dijon Bourgogne University Hospital, Dijon, France
| | - P Joly
- Dermatology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France
| | - P Courville
- Pathology Department, Rouen University Hospital, INSERM U1234, Rouen Institute for Research and Innovation in Biomedicine, Rouen, France
| | - J Rivet
- Dermatology Department, Université de Bordeaux, Bordeaux, France.,Pathology Department, Henri Mondor Hospital, INSERM U955, Université Paris Est, AP-HP, Paris, France
| | - O Dereure
- Dermatology Department, Montpellier University Hospital, Montpellier, France
| | - F Amatore
- Department of Dermatology and Oncodermatology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France
| | - S Taix
- Department of Pathology, Aix-Marseille University, AP-HM, Timone Hospital, Marseille, France
| | - F Grange
- Dermatology Department, Robert Debré University Hospital, Reims, France
| | - A Durlach
- Pathology Department, Reims University Hospital, Reims, France
| | - G Quéreux
- Dermatology Department, Nantes University Hospital, Nantes, France
| | - N Josselin
- Pathology Department, Nantes University Hospital, Nantes, France
| | - I Moulonguet
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - L Mortier
- Dermatology Department, Claude Huriez University Hospital, INSERM U1189, Université de Lille, Lille, France
| | - R Dubois
- Pathology Department, Claude Huriez University Hospital, Lille, France
| | - E Maubec
- Dermatology Department, Avicenne Hospital, AP-HP, Paris, France
| | - L Laroche
- Dermatology Department, Avicenne Hospital, AP-HP, Paris, France
| | - L Michel
- INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | - I Templier
- Dermatology Department, Grenoble University Hospital, Grenoble, France
| | - S Barete
- Dermatology Department, Pité-Salpêtrière Hospital, AP-HP, Paris, France
| | - C Nardin
- Dermatology Department, Minjoz Hospital, Besancon, France, INSERM U1098, University of Franche Comté, EFS Bourgogne Franche-Comté and Franche-Comté University, Besançon, France
| | - O Augereau
- Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France
| | - B Vergier
- Pathology Department, Saint-André Hospital, Bordeaux University Hospital, INSERM U1053 - UMR BaRITOn, Eq 3 Oncogenèse des Lymphomes Cutanés, Université de Bordeaux, Bordeaux, France
| | - M Bagot
- Dermatology Department, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976, Human Immunology Pathophysiology and Immune Therapies, Paris, France.,Université de Paris, Paris, France
| | | |
Collapse
|
22
|
Nardin C, Laheurte C, Puzenat E, Orillard E, Boullerot L, Renaudin A, Godet Y, Borg C, Adotevi O, Aubin F. Immunité spécifique anti-télomérase dans le mélanome. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.08.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Nardin C, Cordonnier M, Chanteloup G, Derangere V, Algros MP, Marcion G, Arnould L, Garrido C, Gobbo J, Aubin F. PD-L1 dans les exosomes circulants de patients atteints de mélanome : un nouveau biomarqueur ? Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.08.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, Romagnoli M, Tonon L, Cavasin P, Novello S, Scarpa R, Farnia A, De Menis E, Rigoli R, Cinetto F, Pauletto P, Agostini C, Rattazzi M. Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives. Am J Hypertens 2020; 33:944-948. [PMID: 32511678 PMCID: PMC7314218 DOI: 10.1093/ajh/hpaa096] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 06/05/2020] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients. METHODS A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020. RESULTS All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341). CONCLUSIONS Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.
Collapse
Affiliation(s)
- Carla Felice
- Acute and Emergency Department, Ca’ Foncello Hospital, Treviso, Italy
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| | - Chiara Nardin
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| | - Gian Luca Di Tanna
- The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Ugo Grossi
- Department of Surgical, Oncologic and Gastroenterological Sciences (DISCOG), Ca’ Foncello Hospital, Treviso, University of Padua, Padua, Italy
| | - Enrico Bernardi
- Acute and Emergency Department, Ca’ Foncello Hospital, Treviso, Italy
| | - Luca Scaldaferri
- Acute and Emergency Department, Ca’ Foncello Hospital, Treviso, Italy
| | - Micaela Romagnoli
- Department of Specialistic and Laboratory Medicine Pulmonology Unit, Ca’ Foncello Hospital, Treviso, Italy
| | - Luca Tonon
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| | - Paola Cavasin
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| | - Simone Novello
- Department of Surgical, Oncologic and Gastroenterological Sciences (DISCOG), Ca’ Foncello Hospital, Treviso, University of Padua, Padua, Italy
| | - Riccardo Scarpa
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| | - Antonio Farnia
- Department of Anesthesia and Intensive Care, Ca’ Foncello Hospital, Treviso, Italy
| | - Ernesto De Menis
- Department of Medicine, Medicina Generale II^, Ca’ Foncello Hospital, Treviso, Italy
| | - Roberto Rigoli
- Department of Specialistic and Laboratory Medicine, Microbiology Unit, Ca’ Foncello Hospital, Treviso, Italy
| | - Francesco Cinetto
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| | - Paolo Pauletto
- O.R.A.S. SpA, Ospedale Riabilitativo di Alta Specializzazione, Motta Di Livenza, Italy
| | - Carlo Agostini
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| | - Marcello Rattazzi
- Department of Medicine—DIMED, Medicina Generale I^, Ca’ Foncello Hospital, Treviso, University of Padova, Padua, Italy
| |
Collapse
|
25
|
Mazzarda F, D'Elia A, Massari R, De Ninno A, Bertani FR, Businaro L, Ziraldo G, Zorzi V, Nardin C, Peres C, Chiani F, Tettey-Matey A, Raspa M, Scavizzi F, Soluri A, Salvatore AM, Yang J, Mammano F. Organ-on-chip model shows that ATP release through connexin hemichannels drives spontaneous Ca 2+ signaling in non-sensory cells of the greater epithelial ridge in the developing cochlea. Lab Chip 2020; 20:3011-3023. [PMID: 32700707 DOI: 10.1039/d0lc00427h] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Prior work supports the hypothesis that ATP release through connexin hemichannels drives spontaneous Ca2+ signaling in non-sensory cells of the greater epithelial ridge (GER) in the developing cochlea; however, direct proof is lacking. To address this issue, we plated cochlear organotypic cultures (COCs) and whole cell-based biosensors with nM ATP sensitivity (ATP-WCBs) at the bottom and top of an ad hoc designed transparent microfluidic chamber, respectively. By performing dual multiphoton Ca2+ imaging, we monitored the propagation of intercellular Ca2+ waves in the GER of COCs and ATP-dependent Ca2+ responses in overlying ATP-WCBs. Ca2+ signals in both COCs and ATP-WCBs were inhibited by supplementing the extracellular medium with ATP diphosphohydrolase (apyrase). Spontaneous Ca2+ signals were strongly depressed in the presence of Gjb6-/- COCs, in which connexin 30 (Cx30) is absent and connexin 26 (Cx26) is strongly downregulated. In contrast, spontaneous Ca2+ signals were not affected by replacement of Panx1-/- with Panx1+/+ COCs in the microfluidic chamber. Similar results were obtained by estimating ATP release from COCs using a classical luciferin-luciferase bioluminescence assay. Therefore, connexin hemichannels and not pannexin 1 channels mediate the release of ATP that is responsible for Ca2+ wave propagation in the developing mouse cochlea. The technological advances presented here have the potential to shed light on a plethora of unrelated open issues that involve paracrine signaling in physiology and pathology and cannot be addressed with standard methods.
Collapse
Affiliation(s)
- Flavia Mazzarda
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy. and Department of Science, Università degli Studi di Roma3, Rome, Italy
| | - Annunziata D'Elia
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy. and Department of Science, Università degli Studi di Roma3, Rome, Italy
| | - Roberto Massari
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy.
| | - Adele De Ninno
- CNR Institute for Photonics and Nanotechnology, Rome, Italy.
| | | | - Luca Businaro
- CNR Institute for Photonics and Nanotechnology, Rome, Italy.
| | - Gaia Ziraldo
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy. and Institute of Otorhinolaryngology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Veronica Zorzi
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy. and Institute of Otorhinolaryngology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Chiara Nardin
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy.
| | - Chiara Peres
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy.
| | - Francesco Chiani
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy.
| | | | - Marcello Raspa
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy.
| | | | - Alessandro Soluri
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy.
| | | | - Jun Yang
- Department of Otorhinolaryngology Head and Neck Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. and Shanghai Key Laboratory of Translational Medicine on Ear and Nose diseases, Shanghai, China
| | - Fabio Mammano
- CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy. and Department of Physics and Astronomy "G. Galilei", University of Padova, Padua, Italy.
| |
Collapse
|
26
|
Kuang Y, Zorzi V, Buratto D, Ziraldo G, Mazzarda F, Peres C, Nardin C, Salvatore AM, Chiani F, Scavizzi F, Raspa M, Qiang M, Chu Y, Shi X, Li Y, Liu L, Shi Y, Zonta F, Yang G, Lerner RA, Mammano F. A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice. EBioMedicine 2020; 57:102825. [PMID: 32553574 PMCID: PMC7378960 DOI: 10.1016/j.ebiom.2020.102825] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 05/22/2020] [Accepted: 05/22/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Numerous currently incurable human diseases have been causally linked to mutations in connexin (Cx) genes. In several instances, pathological mutations generate abnormally active Cx hemichannels, referred to also as "leaky" hemichannels. The goal of this study was to assay the in vivo efficacy of a potent antagonist antibody targeting Cx hemichannels. METHODS We employed the antibody to treat Cx30A88V/A88V adult mutant mice, the only available animal model of Clouston syndrome, a rare orphan disease caused by Cx30 p.A88V leaky hemichannels. To gain mechanistic insight into antibody action, we also performed patch clamp recordings, Ca2+ imaging and ATP release assay in vitro. FINDINGS Two weeks of antibody treatment sufficed to repress cell hyperproliferation in skin and reduce hypertrophic sebaceous glands (SGs) to wild type (wt) levels. These effects were obtained whether mutant mice were treated topically, by application of an antibody cream formulation, or systemically, by intraperitoneal antibody injection. Experiments with mouse primary keratinocytes and HaCaT cells revealed the antibody blocked Ca2+ influx and diminished ATP release through leaky Cx30 p.A88V hemichannels. INTERPRETATION Our results show anti-Cx antibody treatment was effective in vivo and sufficient to counteract the effects of pathological connexin expression in Cx30A88V/A88V mice. In vitro experiments suggest antibodies gained control over leaky hemichannels and contributed to restoring epidermal homeostasis. Therefore, regulating cell physiology by antibodies targeting the extracellular domain of Cxs may enforce an entirely new therapeutic strategy. These findings support the further development of antibodies as drugs to address unmet medical needs for Cx-related diseases. FUND: Fondazione Telethon, GGP19148; University of Padova, SID/BIRD187130; Consiglio Nazionale delle Ricerche, DSB.AD008.370.003\TERABIO-IBCN; National Science Foundation of China, 31770776; Science and Technology Commission of Shanghai Municipality, 16DZ1910200.
Collapse
Affiliation(s)
- Yuanyuan Kuang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, 201210 Shanghai, China; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 200031 Shanghai, China; University of Chinese Academy of Sciences, 100049 Beijing, China
| | - Veronica Zorzi
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Institute of Otorhinolaryngology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Damiano Buratto
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Gaia Ziraldo
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Institute of Otorhinolaryngology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Flavia Mazzarda
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Science, Roma3 University, 00146 Rome, Italy
| | - Chiara Peres
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Physics and Astronomy "G. Galilei", University of Padova, 35131 Padova, Italy
| | - Chiara Nardin
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Physics and Astronomy "G. Galilei", University of Padova, 35131 Padova, Italy
| | | | - Francesco Chiani
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy
| | | | - Marcello Raspa
- CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy
| | - Min Qiang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Youjun Chu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Xiaojie Shi
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Yu Li
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, 201210 Shanghai, China; Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 200031 Shanghai, China; University of Chinese Academy of Sciences, 100049 Beijing, China
| | - Lili Liu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Yaru Shi
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Francesco Zonta
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China
| | - Guang Yang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.
| | - Richard A Lerner
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, U.S.A..
| | - Fabio Mammano
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; CNR Institute of Biochemistry and Cell Biology, 00015 Monterotondo, Italy; Department of Physics and Astronomy "G. Galilei", University of Padova, 35131 Padova, Italy.
| |
Collapse
|
27
|
Yu S, Middlemiss JE, Nardin C, Hickson SS, Miles KL, Yasmin, Maki-Petaja KM, McDonnell BJ, Cockcroft JR, Wilkinson IB, McEniery CM. Role of Vascular Adaptation in Determining Systolic Blood Pressure in Young Adults. J Am Heart Assoc 2020; 9:e014375. [PMID: 33044913 PMCID: PMC7428627 DOI: 10.1161/jaha.119.014375] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Background Two individuals can have a similar pulse pressure (PP) but different levels of systolic blood pressure (SBP), although the underlying mechanisms have not been described. We hypothesized that, for a given level of PP, differences in SBP relate to peripheral vascular resistance (PVR); and we tested this hypothesis in a large cohort of healthy young adults. Methods and Results Demographic, biochemical, and hemodynamic data from 3103 subjects were available for the current analyses. In both men and women, for a given level of PP, higher SBP was associated with significantly higher body weight, body mass index, heart rate, and PVR (P<0.05 versus those with lower BP for all comparisons). Moreover, stratifying individuals by quartiles of PP and PVR revealed a stepwise increase in SBP from the lowest to highest quartile for each variable, with the highest SBP occurring in those in the highest quartile of both PP and PVR (P<0.001 for overall trend for both sexes). PVR was also increased with increasing tertile of minimum forearm vascular resistance, in both men (P=0.002) and women (P=0.03). Conclusions Increased PVR, mediated in part through altered resistance vessel structure, strongly associates with the elevation of SBP for a given level of PP in young adults. An impaired ability to adapt PVR appropriately to a given level of PP may be an important mechanism underlying elevated SBP in young adults.
Collapse
Affiliation(s)
- Shikai Yu
- Department of Cardiology Shanghai Tenth People's Hospital Tongji University School of Medicine Shanghai China.,Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Jessica E Middlemiss
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Chiara Nardin
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom.,Dipartimento di Medicina (DIMED) University of Padova Italy
| | - Stacey S Hickson
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Karen L Miles
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Yasmin
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Kaisa M Maki-Petaja
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Barry J McDonnell
- Cardiff School of Health Sciences Cardiff Metropolitan University Cardiff United Kingdom
| | - John R Cockcroft
- Cardiff School of Health Sciences Cardiff Metropolitan University Cardiff United Kingdom
| | - Ian B Wilkinson
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Carmel M McEniery
- Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | | |
Collapse
|
28
|
Saiag P, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C. Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Dutriaux C, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P. An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Nardin C, Cordonnier M, Chanteloup G, Derangere V, Algros M, Arnould L, Garrido C, Aubin F, Gobbo J. 521 Circulating PD-L1-exosomes to monitor tumor response in melanoma patients. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Ziraldo G, Buratto D, Kuang Y, Xu L, Carrer A, Nardin C, Chiani F, Salvatore AM, Paludetti G, Lerner RA, Yang G, Zonta F, Mammano F. A Human-Derived Monoclonal Antibody Targeting Extracellular Connexin Domain Selectively Modulates Hemichannel Function. Front Physiol 2019; 10:392. [PMID: 31263420 PMCID: PMC6584803 DOI: 10.3389/fphys.2019.00392] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 03/21/2019] [Indexed: 11/30/2022] Open
Abstract
Connexin hemichannels, which are plasma membrane hexameric channels (connexons) composed of connexin protein protomers, have been implicated in a host of physiological processes and pathological conditions. A number of single point pathological mutations impart a “leaky” character to the affected hemichannels, i.e., make them more active or hyperactive, suggesting that normal physiological condition could be recovered using selective hemichannel inhibitors. Recently, a human-derived monoclonal antibody named abEC1.1 has been shown to inhibit both wild type and hyperactive hemichannels composed of human (h) connexin 26 (hCx26) subunits. The aims of this work were (1) to characterize further the ability of abEC1.1 to selectively modulate connexin hemichannel function and (2) to assess its in vitro stability in view of future translational applications. In silico analysis of abEC1.1 interaction with the hCx26 hemichannel identified critically important extracellular domain amino acids that are conserved in connexin 30 (hCx30) and connexin 32 (hCx32). Patch clamp experiments performed in HeLa DH cells confirmed the inhibition efficiency of abEC1.1 was comparable for hCx26, hCx30 and hCx32 hemichannels. Of note, even a single amino acid difference in the putative binding region reduced drastically the inhibitory effects of the antibody on all the other tested hemichannels, namely hCx30.2/31.3, hCx30.3, hCx31, hCx31.1, hCx37, hCx43 and hCx45. Plasma membrane channels composed of pannexin 1 were not affected by abEC1.1. Finally, size exclusion chromatography assays showed the antibody does not aggregate appreciably in vitro. Altogether, these results indicate abEC1.1 is a promising tool for further translational studies.
Collapse
Affiliation(s)
- Gaia Ziraldo
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Institute of Otolaryngology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Damiano Buratto
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
| | - Yuanyuan Kuang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
| | - Liang Xu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
| | - Andrea Carrer
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Department of Physics and Astronomy "G. Galilei", University of Padova, Padua, Italy
| | - Chiara Nardin
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Department of Physics and Astronomy "G. Galilei", University of Padova, Padua, Italy
| | - Francesco Chiani
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy
| | | | - Gaetano Paludetti
- Institute of Otolaryngology, Università Cattolica del Sacro Cuore, Rome, Italy.,Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Richard A Lerner
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
| | - Guang Yang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
| | - Francesco Zonta
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
| | - Fabio Mammano
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.,Department of Physics and Astronomy "G. Galilei", University of Padova, Padua, Italy
| |
Collapse
|
32
|
Affiliation(s)
- C Nardin
- Dermatologie, Centre Hospitalier de Belfort Montbéliard, Montbéliard
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| | - A S Dupond
- Dermatologie, Centre Hospitalier de Belfort Montbéliard, Montbéliard
| | - F Pelletier
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| | - E Puzenat
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| | - F Aubin
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| |
Collapse
|
33
|
Affiliation(s)
- C Nardin
- Dermatologie, Centre Hospitalier de Belfort Montbéliard, Montbéliard
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| | - A S Dupond
- Dermatologie, Centre Hospitalier de Belfort Montbéliard, Montbéliard
| | - F Pelletier
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| | - E Puzenat
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| | - F Aubin
- Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
| |
Collapse
|
34
|
Castagna J, Parrens M, Nardin C, Angonin R, Bedgedjian I, Vergier B, Merlio J, Aubin F, Beylot-Barry M. Primary cutaneous peripheral T-cell lymphoma not otherwise specified: a comparative clinicopathological analysis of 5 cases. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30576-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Nardin C, Maki-Petaja KM, Miles KL, Yasmin, McDonnell BJ, Cockcroft JR, Wilkinson IB, McEniery CM. Cardiovascular Phenotype of Elevated Blood Pressure Differs Markedly Between Young Males and Females: The Enigma Study. Hypertension 2018; 72:1277-1284. [PMID: 30763511 PMCID: PMC6221425 DOI: 10.1161/hypertensionaha.118.11975] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 08/25/2018] [Accepted: 09/19/2018] [Indexed: 01/12/2023]
Abstract
Blood pressure (BP) in young adults predicts BP in later life. We aimed to identify metabolic, hemodynamic, and autonomic characteristics associated with raised BP in young adults and whether these differ between males and females. Three thousand one hundred forty-five healthy subjects, aged 18 to 40 years, were grouped according to sex and BP category following the recent reclassification of BP as part of American Heart Association/American College of Cardiology 2017 guidelines. All individuals undertook a lifestyle and medical history questionnaire and detailed metabolic, hemodynamic, and autonomic assessments. Stage 1 hypertension and normal BP were the most common BP phenotypes in males (29%) and females (68%), respectively. In both sexes, cardiac output was positively associated with increasing BP category (P<0.001 for both). Similar positive trends were observed for heart rate and stroke volume in males (P<0.001 for both) and heart rate in females (P<0.001). Unlike in males, peripheral vascular resistance, aortic pulse wave velocity, and augmentation index were significantly increased in hypertensive females (P<0.001 for all) compared with the other BP categories. Most heart rate variability indices decreased across the BP categories, particularly in males. In young adults, metabolic and hemodynamic abnormalities associated with hypertension are already present at the elevated BP stage and the overall phenotype differed markedly between sexes. Whereas a cardiac phenotype was associated with elevated BP and hypertension in males, a vascular phenotype, characterized by elevated peripheral vascular resistance, aortic pulse wave velocity, and augmentation index, was dominant in females.
Collapse
Affiliation(s)
- Chiara Nardin
- From the Department of Medicine-DIMED, University of Padova, Italy (C.N.)
- Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (C.N., K.M.M.-P., K.L.M., Y., I.B.W., C.M.M.)
| | - Kaisa M. Maki-Petaja
- Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (C.N., K.M.M.-P., K.L.M., Y., I.B.W., C.M.M.)
| | - Karen L. Miles
- Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (C.N., K.M.M.-P., K.L.M., Y., I.B.W., C.M.M.)
| | - Yasmin
- Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (C.N., K.M.M.-P., K.L.M., Y., I.B.W., C.M.M.)
| | - Barry J. McDonnell
- Cardiff School of Health Sciences, Cardiff Metropolitan University, United Kingdom (B.J.M., J.R.C.)
| | - John R. Cockcroft
- Cardiff School of Health Sciences, Cardiff Metropolitan University, United Kingdom (B.J.M., J.R.C.)
| | - Ian B. Wilkinson
- Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (C.N., K.M.M.-P., K.L.M., Y., I.B.W., C.M.M.)
| | - Carmel M. McEniery
- Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (C.N., K.M.M.-P., K.L.M., Y., I.B.W., C.M.M.)
| |
Collapse
|
36
|
Rattazzi M, Faggin E, Bertacco E, Nardin C, Pagliani L, Plebani M, Cinetto F, Guidolin D, Puato M, Pauletto P. Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE-/- mice. Cardiovasc Ther 2018; 36:e12438. [PMID: 29847020 DOI: 10.1111/1755-5922.12438] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 05/16/2018] [Accepted: 05/22/2018] [Indexed: 12/17/2022] Open
Abstract
INTRODUCTION Vitamin K antagonists, such as warfarin, are known to promote arterial calcification through blockade of gamma-carboxylation of Matrix-Gla-Protein. It is currently unknown whether other oral anticoagulants such as direct inhibitors of Factor Xa can have protective effects on the progression of aortic valve calcification. AIMS To compare the effect of warfarin and rivaroxaban on the progression of aortic valve calcification in atherosclerotic mice. RESULTS 42 ApoE-/- mice fed with Western-type Diet (WTD) were randomized to treatment with warfarin (n = 14), rivaroxaban (n = 14) or control (n = 14) for 8 weeks. Histological analyses were performed to quantify the calcification of aortic valve leaflets and the development of atherosclerosis. The analyses showed a significant increase in valve calcification in mice treated with warfarin as compared to WTD alone (P = .025) or rivaroxaban (P = .005), whereas no significant differences were found between rivaroxaban and WTD (P = .35). Quantification of atherosclerosis and intimal calcification was performed on the innominate artery of the mice and no differences were found between the 3 treatments as far as atherogenesis and calcium deposition is concerned. In vitro experiments performed using bovine interstitial valve cells (VIC) showed that treatment with rivaroxaban did not prevent the osteogenic conversion of the cells but reduce the over-expression of COX-2 induced by inflammatory mediators. CONCLUSION We showed that warfarin, but not rivaroxaban, could induce calcific valve degeneration in a mouse model of atherosclerosis. Both the treatments did not significantly affect the progression of atherosclerosis. Overall, these data suggest a safer profile of rivaroxaban on the risk of cardiovascular disease progression.
Collapse
Affiliation(s)
- Marcello Rattazzi
- Department of Medicine - DIMED, University of Padova, Padova, Italy.,Medicina Generale I^, Ca' Foncello Hospital, Treviso, Italy
| | | | - Elisa Bertacco
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| | - Chiara Nardin
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| | | | - Mario Plebani
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| | - Francesco Cinetto
- Department of Medicine - DIMED, University of Padova, Padova, Italy.,Medicina Generale I^, Ca' Foncello Hospital, Treviso, Italy
| | - Diego Guidolin
- Department of Neuroscience, University of Padova, Padova, Italy
| | - Massimo Puato
- Department of Medicine - DIMED, University of Padova, Padova, Italy
| | - Paolo Pauletto
- ORAS Rehabilitation Hospital, Motta di Livenza, Treviso, Italy
| |
Collapse
|
37
|
Puato M, Nardin C, Zanon M, Palatini P, Pauletto P, Rattazzi M. Vascular Remodelling in Well-controlled Hypertensive Patients: The Challenge of Residual Risk Management. Curr Pharm Des 2018; 23:1445-1452. [PMID: 28245758 DOI: 10.2174/1381612823666170228122644] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Accepted: 02/22/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Residual cardiovascular risk (RCVR) is an emerging issue in the clinical and therapeutic management of patients affected by hypertension. In fact, a number of clinical studies showed that even in case of optimal blood pressure (BP) control, the hypertensive patients still carry a sizeable increase in the CV risk as compared to normotensive individuals. METHODS We will review the clinical evidence about the determinants and the impact of RCVR on hypertension, with a specific focus on the progression of vascular damage. RESULTS The presence of RCVR in hypertensive patients is a significant phenomenon which challenges our clinical effort far beyond the reaching of BP targets. Although major determinants of RCVR are still undefined, there is a clear indication about the importance of an early and sustained control of BP values, so as to prevent the onset of target organ damage. In fact, our data and findings from the literature indicate that the &quot;pseudo-normalization&quot; of BP is not sufficient to abolish the risk of pro-atherogenic remodeling of arterial vessels. CONCLUSION Additional studies are needed to establish whether the intervention on specific BP profiles and inflammatory mechanisms can have some clinical relevance in the management of RCVR. In the meanwhile, the precise phenotyping of the CV risk profile of each patient, coupled with a tailored pharmacological approach, represents the most effective strategy to hinder the progression of vascular damage and reduce the RCVR.
Collapse
Affiliation(s)
- Massimo Puato
- Department of Medicine - DIMED, University of Padova, Medicina Interna I. , Ospedale Ca' Foncello, Via Ospedale 1, 31100 Treviso
| | - Chiara Nardin
- Department of Medicine - DIMED, University of Padova, Medicina Interna I. , Ospedale Ca' Foncello, Via Ospedale 1, 31100 Treviso
| | - Marta Zanon
- Department of Medicine - DIMED, University of Padova, Medicina Interna I. , Ospedale Ca' Foncello, Via Ospedale 1, 31100 Treviso
| | - Paolo Palatini
- Department of Medicine - DIMED, University of Padova, Medicina Interna I. , Ospedale Ca' Foncello, Via Ospedale 1, 31100 Treviso
| | - Paolo Pauletto
- Department of Medicine - DIMED, University of Padova, Medicina Interna I. , Ospedale Ca' Foncello, Via Ospedale 1, 31100 Treviso
| | - Marcello Rattazzi
- Department of Medicine - DIMED, University of Padova, Medicina Interna I. , Ospedale Ca' Foncello, Via Ospedale 1, 31100 Treviso
| |
Collapse
|
38
|
Nardin C, Maki-Petaja K, Yasmin Y, McDonnell B, Cockcroft JR, Wilkinson IB, McEniery CM. P116 CARDIAC OUTPUT IS INCREASED IN YOUNG PEOPLE WITH ELEVATED BP. Artery Res 2018. [DOI: 10.1016/j.artres.2018.10.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
39
|
Aubin F, Courtois J, Puzenat E, Nardin C, Castelain F, Pelletier F, Gastaldi-Ménager C. Phototherapy in France: quantitative data (2007-2016) from the National Health Insurance Register. J Eur Acad Dermatol Venereol 2017; 32:e224-e225. [DOI: 10.1111/jdv.14746] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- F. Aubin
- Department of Dermatology; University of Bourgogne Franche Comté, EA3181 and University Hospital; Besançon France
| | - J. Courtois
- Caisse Nationale d'Assurance Maladie; Paris France
| | - E. Puzenat
- Department of Dermatology; University of Bourgogne Franche Comté, EA3181 and University Hospital; Besançon France
| | - C. Nardin
- Department of Dermatology; University of Bourgogne Franche Comté, EA3181 and University Hospital; Besançon France
| | - F. Castelain
- Department of Dermatology; University of Bourgogne Franche Comté, EA3181 and University Hospital; Besançon France
| | - F. Pelletier
- Department of Dermatology; University of Bourgogne Franche Comté, EA3181 and University Hospital; Besançon France
| | | | | |
Collapse
|
40
|
Nardin C, Colas M, Curie V, Pelletier F, Puzenat E, Aubin F. Grossesse compliquée d’un avortement spontané précoce après stérilisation tubaire chez une patiente traitée par sécukinumab pour un psoriasis. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Nardin C, Colas M, Badoz M, Roche-Kubler B, Méneveau N, Puzenat E, Aubin F. Syndrome de Brugada induit par l’association anti-BRAF et anti-MEK au cours d’un mélanome métastatique. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Jacquin-Porretaz C, Gérard B, Nardin C, Drobacheff-Thiébaut M, Blanc D, Jacoulet P, Westeel V, Aubin F. Toxicité cutanée de l’erlotinib induite par la prise de thé à l’hibiscus. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
43
|
Zorzi V, Paciello F, Ziraldo G, Peres C, Mazzarda F, Nardin C, Pasquini M, Chiani F, Raspa M, Scavizzi F, Carrer A, Crispino G, Ciubotaru CD, Monyer H, Fetoni AR, M Salvatore A, Mammano F. Mouse Panx1 Is Dispensable for Hearing Acquisition and Auditory Function. Front Mol Neurosci 2017; 10:379. [PMID: 29234270 PMCID: PMC5712377 DOI: 10.3389/fnmol.2017.00379] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 10/30/2017] [Indexed: 11/13/2022] Open
Abstract
Panx1 forms plasma membrane channels in brain and several other organs, including the inner ear. Biophysical properties, activation mechanisms and modulators of Panx1 channels have been characterized in detail, however the impact of Panx1 on auditory function is unclear due to conflicts in published results. To address this issue, hearing performance and cochlear function of the Panx1−/− mouse strain, the first with a reported global ablation of Panx1, were scrutinized. Male and female homozygous (Panx1−/−), hemizygous (Panx1+/−) and their wild type (WT) siblings (Panx1+/+) were used for this study. Successful ablation of Panx1 was confirmed by RT-PCR and Western immunoblotting in the cochlea and brain of Panx1−/− mice. Furthermore, a previously validated Panx1-selective antibody revealed strong immunoreactivity in WT but not in Panx1−/− cochleae. Hearing sensitivity, outer hair cell-based “cochlear amplifier” and cochlear nerve function, analyzed by auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) recordings, were normal in Panx1+/− and Panx1−/− mice. In addition, we determined that global deletion of Panx1 impacts neither on connexin expression, nor on gap-junction coupling in the developing organ of Corti. Finally, spontaneous intercellular Ca2+ signal (ICS) activity in organotypic cochlear cultures, which is key to postnatal development of the organ of Corti and essential for hearing acquisition, was not affected by Panx1 ablation. Therefore, our results provide strong evidence that, in mice, Panx1 is dispensable for hearing acquisition and auditory function.
Collapse
Affiliation(s)
- Veronica Zorzi
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,School of Medicine, Institute of Otolaryngology, Catholic University, Rome, Italy
| | - Fabiola Paciello
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy
| | - Gaia Ziraldo
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,School of Medicine, Institute of Otolaryngology, Catholic University, Rome, Italy
| | - Chiara Peres
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy
| | - Flavia Mazzarda
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Department of Science, Roma Tre University, Rome, Italy
| | - Chiara Nardin
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Department of Science, Roma Tre University, Rome, Italy
| | - Miriam Pasquini
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Rome, Italy
| | - Francesco Chiani
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy
| | - Marcello Raspa
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy
| | | | - Andrea Carrer
- Department of Physics and Astronomy G. Galilei, University of Padua, Padua, Italy
| | - Giulia Crispino
- Department of Physics and Astronomy G. Galilei, University of Padua, Padua, Italy
| | | | - Hannah Monyer
- Department of Clinical Neurobiology, Deutches Krebforschungzentrum, University of Heidelberg, Heidelberg, Germany
| | - Anna R Fetoni
- School of Medicine, Institute of Otolaryngology, Catholic University, Rome, Italy
| | - Anna M Salvatore
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy
| | - Fabio Mammano
- CNR Institute of Cell Biology and Neurobiology, Monterotondo, Italy.,Department of Physics and Astronomy G. Galilei, University of Padua, Padua, Italy.,Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China
| |
Collapse
|
44
|
Xu L, Carrer A, Zonta F, Qu Z, Ma P, Li S, Ceriani F, Buratto D, Crispino G, Zorzi V, Ziraldo G, Bruno F, Nardin C, Peres C, Mazzarda F, Salvatore AM, Raspa M, Scavizzi F, Chu Y, Xie S, Yang X, Liao J, Liu X, Wang W, Wang S, Yang G, Lerner RA, Mammano F. Design and Characterization of a Human Monoclonal Antibody that Modulates Mutant Connexin 26 Hemichannels Implicated in Deafness and Skin Disorders. Front Mol Neurosci 2017; 10:298. [PMID: 29018324 PMCID: PMC5615210 DOI: 10.3389/fnmol.2017.00298] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Accepted: 09/05/2017] [Indexed: 12/21/2022] Open
Abstract
Background: Mutations leading to changes in properties, regulation, or expression of connexin-made channels have been implicated in 28 distinct human hereditary diseases. Eight of these result from variants of connexin 26 (Cx26), a protein critically involved in cell-cell signaling in the inner ear and skin. Lack of non-toxic drugs with defined mechanisms of action poses a serious obstacle to therapeutic interventions for diseases caused by mutant connexins. In particular, molecules that specifically modulate connexin hemichannel function without affecting gap junction channels are considered of primary importance for the study of connexin hemichannel role in physiological as well as pathological conditions. Monoclonal antibodies developed in the last three decades have become the most important class of therapeutic biologicals. Recombinant methods permit rapid selection and improvement of monoclonal antibodies from libraries with large diversity. Methods: By screening a combinatorial library of human single-chain fragment variable (scFv) antibodies expressed in phage, we identified a candidate that binds an extracellular epitope of Cx26. We characterized antibody action using a variety of biochemical and biophysical assays in HeLa cells, organotypic cultures of mouse cochlea and human keratinocyte-derived cells. Results: We determined that the antibody is a remarkably efficient, non-toxic, and completely reversible inhibitor of hemichannels formed by connexin 26 and does not affect direct cell-cell communication via gap junction channels. Importantly, we also demonstrate that the antibody efficiently inhibits hyperative mutant Cx26 hemichannels implicated in autosomal dominant non-syndromic hearing impairment accompanied by keratitis and hystrix-like ichthyosis-deafness (KID/HID) syndrome. We solved the crystal structure of the antibody, identified residues that are critical for binding and used molecular dynamics to uncover its mechanism of action. Conclusions: Although further studies will be necessary to validate the effect of the antibody in vivo, the methodology described here can be extended to select antibodies against hemichannels composed by other connexin isoforms and, consequently, to target other pathologies associated with hyperactive hemichannels. Our study highlights the potential of this approach and identifies connexins as therapeutic targets addressable by screening phage display libraries expressing human randomized antibodies.
Collapse
Affiliation(s)
- Liang Xu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China.,Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of SciencesShanghai, China
| | - Andrea Carrer
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Physics and Astronomy "G. Galilei,", University of PadovaPadova, Italy
| | - Francesco Zonta
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China.,CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy
| | - Zhihu Qu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Peixiang Ma
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Sheng Li
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Federico Ceriani
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Physics and Astronomy "G. Galilei,", University of PadovaPadova, Italy
| | - Damiano Buratto
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Physics and Astronomy "G. Galilei,", University of PadovaPadova, Italy
| | - Giulia Crispino
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Physics and Astronomy "G. Galilei,", University of PadovaPadova, Italy.,Venetian Institute of Molecular MedicinePadova, Italy
| | - Veronica Zorzi
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Institute of Otolaryngology, Catholic University School of MedicineRome, Italy
| | - Gaia Ziraldo
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Physics and Astronomy "G. Galilei,", University of PadovaPadova, Italy.,Institute of Otolaryngology, Catholic University School of MedicineRome, Italy
| | - Francesca Bruno
- Department of Physics and Astronomy "G. Galilei,", University of PadovaPadova, Italy.,Venetian Institute of Molecular MedicinePadova, Italy
| | - Chiara Nardin
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Science, Roma Tre UniversityRome, Italy
| | - Chiara Peres
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy
| | - Flavia Mazzarda
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Science, Roma Tre UniversityRome, Italy
| | - Anna M Salvatore
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy
| | - Marcello Raspa
- CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy
| | | | - Youjun Chu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Sichun Xie
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Xuemei Yang
- School of Life Science and Technology, Shanghai Tech UniversityShanghai, China
| | - Jun Liao
- School of Life Science and Technology, Shanghai Tech UniversityShanghai, China
| | - Xiao Liu
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China.,Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of SciencesShanghai, China.,University of Chinese Academy of SciencesBeijing, China
| | - Wei Wang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Shanshan Wang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Guang Yang
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China
| | - Richard A Lerner
- Department of Cell and Molecular Biology, The Scripps Research InstituteLa Jolla, CA, United States
| | - Fabio Mammano
- Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai, China.,CNR Institute of Cell Biology and NeurobiologyMonterotondo, Italy.,Department of Physics and Astronomy "G. Galilei,", University of PadovaPadova, Italy.,Venetian Institute of Molecular MedicinePadova, Italy
| |
Collapse
|
45
|
Nardin C, Mateus C, Texier M, Lanoy E, Hibat-Allah S, Ammari S, Robert C, Dhermain F. Tolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma brain metastases. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Nardin C, Mateus C, Texier M, Lanoy E, Hibat-Allah S, Ammari S, Robert C, Dhermain F. Tolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma brain metastases. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Puzenat E, Nardin C, Boccara O, Eschard C, Bayaram M, Aubin F. Efficacité des mTOR inhibiteurs dans le syndrome de Kasabach-Merritt associé à un angiome en touffe. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
48
|
Nardin C, Mateus C, Texier M, Lanoy E, Hibat-Allah S, Ammari S, Robert C, Dhermain F. Tolérance de la radiothérapie stéréotaxique cérébrale chez les patients traités par pembrolizumab pour un mélanome métastatique. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Zhou D, Halaban R, Bacchiocchi A, Nardin C, Zippin J. 606 The pH sensor soluble adenylyl cyclase regulates melanogenesis. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Nardin C, Locatelli F, Puzenat E, Jeand’heur A, Moreau J, Castagna J, Aubin F. Intérêt du lanréotide dans le traitement du carcinome de Merckel métastatique. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|